Spondyloarthritis & psoriatic arthritis
Annual trends of chronic opioid use in patients with inflammatory bowel disease and spondyloarthritis in Denmark between 2000 and 2023
Authors' conclusion
Despite overall reductions in opioid prescribing, COU, particularly strong opioid use, remains disproportionately high among patients with IBD + SpA.
Study context
- Population
- Patients with Crohn's disease or ulcerative colitis in Denmark, 2000–202313,417 (2000) to 51,230 (2023) inflammatory bowel disease (IBD) patients
- Exposure
- IBD with spondyloarthritis (SpA) vs IBD without SpA
- Outcome
- Annual proportion of chronic opioid use (≥3 opioid prescriptions within 12 months, separated by ≥30 days)
- Follow-up
- 2000 to 2023
Methodological detailsnationwide Danish health registers, descriptive temporal trends, logistic regression with robust variance
- Nationwide Danish health registers
- Descriptive temporal trends
- Logistic regression with robust variance
Main finding
As reported in the abstract
Chronic opioid use, 2000 to 2023
IBD + SpA
27.0% to 13.7%
IBD without SpA
9.8% to 5.7%
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | IBD + SpA | P value |
|---|---|---|
| Chronic strong opioid use (subgroup analysis) · 2000 to 2023 | 3.6% to 6.2% | P < 0.001 |
Chronic strong opioid use (subgroup analysis) · 2000 to 2023
- Remained stable in patients without SpA
Proportion of IBD population with SpA · 2000 to 2023
- Proportion with SpA increased
- 1.6% to 5.5%
Original publication
Annual trends of chronic opioid use in patients with inflammatory bowel disease and spondyloarthritis in Denmark between 2000 and 2023. Scand J Rheumatol. Published 1 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →